Renaissance Pharma is a global biopharmaceutical company intent on developing and commercialising novel paediatric oncology therapeutics to bring life-enhancing benefits to children across the world

Based in the United Kingdom, Renaissance Pharma is a clinical stage pharmaceutical company with a mission to develop and commercialise clinically meaningful, novel therapeutics that will bring life-enhancing benefits to children across the world.

The company’s lead asset, a humanised anti-GD2 antibody called Hu14.18K322A (Hu14.18) has completed Phase II trials, where it showed significant improvement in clinical outcomes for children with newly diagnosed high-risk neuroblastoma. A combination of treatment with Hu14.18 and chemotherapy led to an overall survival rate of 86%, with potential for reduced immunogenicity and tolerability compared to the current standard of care.